Loading...
Loading...
Aegerion Pharmaceuticals,
Inc.
AEGR, an emerging biopharmaceutical company focused on the
development and commercialization of novel therapeutics to treat debilitating
and often fatal rare diseases, today announced that the U.S. Food and Drug
Administration (FDA) has scheduled a meeting of the Endocrinologic and
Metabolic Drugs Advisory Committee on October 17, 2012, to review the
Company's New Drug Application for lomitapide in the treatment of adult
patients with Homozygous Familial Hypercholesterolemia (HoFH). Details of the
meeting will be available in the Federal Register.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in